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Typing somatostatin receptor expression in neuroendocrine tumors is of relevance to target somatostatin
analogue-based diagnostic approach and treatment. The expanding use of immunohistochemistry to detect
somatostatin receptors is to date not paralleled by an accurate methodological setting and standardized
interpretation of the results. A multicentric study was designed to compare somatostatin receptor
immunohistochemical expression with in vivo scintigraphic data and verify its usefulness in the clinical
management of neuroendocrine tumors. After methodological setting by testing different somatostatin receptor
antibodies, 107 cases of neuroendocrine tumors with available somatostatin receptor scintigraphy data and
pathological material were retrospectively analyzed for somatostatin receptor types 2A, 3 and 5 immunohis-
tochemical expression, and compared with scintigraphic images and, whenever available, with the clinical
response to somatostatin analogue treatment. Restricting ‘positive cases’ to the presence of a membrane
pattern of staining, an overall somatostatin receptor type 2A immunohistochemistry/somatostatin receptor
scintigraphy agreement of 77% (v2 test Po0.0001) was reached. Lower concordance ratios were detected in
preoperative and metastatic tumor samples, possibly as a consequence of somatostatin receptor expression
heterogeneity. Pure somatostatin receptor type 2A cytoplasmic staining showed poor correlation with
somatostatin receptor scintigraphy (54% concordance rate). The immunohistochemical detection of
somatostatin receptor types 3 and 5, which showed almost exclusively a cytoplasmic pattern, did not improve
the concordance with scintigraphic data. In a pilot series, somatostatin receptor type 2A immunohistochemistry
correlated with clinical response in 75% of cases. In conclusion, we propose a scoring system for somatostatin
receptor type 2A immunohistochemistry in neuroendocrine tumors correlated with in vivo data, based on
the evidence that only membrane (rather that cytoplasmic) staining should be considered for a reliable,
standardized and clinically relevant report.
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Neuroendocrine tumors belong to a spectrum of
lesions with variable degree of differentiation and
have various locations and various disease stages:
carcinoids (benign and malignant or typical and
atypical) lie in the well differentiated extreme of the
spectrum, while small and large cell neuroendo-
crine carcinomas represent the poorly differentiated
variants.1,2
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There are several therapeutic options for neuroen-
docrine tumors. Apart from surgery, chemotherapy
and biotherapy are generally the first line treat-
ments. The latter includes in both functioning and
non-functioning neuroendocrine tumors somatosta-
tin analogue administration, both in medical treat-
ment and as radio-labeled agents, and interferon.3–5
Somatostatin is an acidic polypeptide that is
widely distributed throughout the central nervous
system and different peripheral tissues and organs.
Several biological functions related to somatostatin
have been described, and include potent inhibition
of basal and stimulated secretion from a wide
variety of endocrine and exocrine cells, neuromo-
dulatory actions in the central nervous system6–9 as
well as regulatory properties on cell proliferation
and differentiation.10 The physiological actions of
somatostatin are initiated by its interaction with a
family of specific membrane-bound receptors, the
somatostatin receptors family, which encompass to
date five different subtypes, named somatostatin
receptors types 1–5, displaying a remarkable degree
of structural conservation across species (40–60%
structural homologies), but mediating different
biological actions of somatostatin, via the activation
of different intracellular signaling pathways.11,12
The rationale for somatostatin analogue (eg octreo-
tide) treatment is the presence of somatostatin
receptors on the surface of tumor cells. These bind
octreotide with different degrees of affinity, being
somatostatin receptors types 2, 3 and 5 those mostly
involved in octreotide binding.
In the clinical practice, the presence of functional
somatostatin receptors is documented by somatos-
tatin receptor scintigraphy by 111In-pentetreotide: if
positive, a binding of the radioligand with one or
more of the somatostatin receptors is demonstrated.
Unfortunately, this technique does not identify the
receptor type and—most importantly—does not
determine the cell population containing the bind-
ing sites (tumor cells vs other intratumoral cell
types). Various methods to detect somatostatin
receptors in tumor specimens were reported, in-
cluding autoradiography, RT-PCR, in situ hybridiza-
tion, immunoblotting and immunohistochemistry.
Several studies have documented that generally
these methods correlate each other in somatostatin
receptors positive cases, with only minor discre-
pancies.13–22
The currently available somatostatin analogues
bind preferentially somatostatin receptors type 2
(which is the most widely expressed subtype in
neuroendocrine tumors) and to a lower extent types
3 and 5, and somatostatin receptors profiling in
individual patients may be of relevance to better
tailor the somatostatin analogue-based treatment.
This would hopefully allow to increase the response
rate of each patient and reduce costs of biotherapy,
which are generally high.
Immunohistochemistry is a cheap, reproducible,
and easily accessible procedure that can be per-
formed in most pathology laboratories on fresh and
also archival tissue samples. Commercially available
antibodies specific for the different receptor sub-
types are currently available, but they need to be
validated in the clinical practice. No data exist in
fact on the quantification and interpretation of
somatostatin receptor immunohistochemical find-
ings, although scoring systems have been developed
and applied for many years in the analysis of several
other receptors (eg estrogen receptor, c-erb-b2, etc).
Aim of the present study is therefore to define the
somatostatin receptors immunohistochemical pro-
file in a large series of neuroendocrine tumors of
which surgical and/or biopsy material were avail-
able, and compare the results with the in vivo data
on 111In-pentetreotide scintigraphy and response to
somatostatin analogue treatment.
Materials and methods
Case Selection
A series of 107 neuroendocrine tumors (from years
1998 to 2006) treated in three different highly
specialized Italian centers of the Universities of
Turin, Naples and Varese was selected according to
the following criteria: (i) revised histopathological
diagnosis; (ii) tissue material available for patholo-
gical review and immunohistochemistry; (iii) 111In-
pentetreotide scintigraphy data available.
For most cases, medical treatment administered,
response to treatment (as progressive disease, partial
remission or stable disease) and follow-up data were
also accessible.
Somatostatin receptor scintigraphy was per-
formed preoperatively in all but seven patients,
who had post-surgical somatostatin receptor
scintigraphy in the presence of residual disease.
111Indium-DTPA0-octreotide (135 MBq) was admi-
nistered immediately after checking the specific
radiochemical purity by chromatography, which
was always higher than 95%. The scintigraphic
procedure included 4- and 24-h planar anterior and
posterior images (matrix size 128 128) of the chest,
upper and lower abdomen and anterior views of the
head and proximal lower legs. At least 500 Kilo-
counts were recorded over the chest and abdomen
and 50–200 Kilocounts were obtained for the head
and neck and lower leg views. SPECF of the
abdomen was performed 24 h after injection. Sixty-
four 40-s views (matrix size: 64 64) were acquired
through a 3601 arc. Planar and SPECF images were
acquired using a large field of view g camera
equipped with a medium-energy, general-purpose
collimator. Somatostatin receptor scintigraphy
images were scored in four groups according to
Kwekkeboom et al.23
The tissue material corresponded to 41 preopera-
tive samples (fine-needle aspiration or core biop-
sies) and 66 surgical samples. All surgical samples
were fixed in buffered formalin; preoperative sam-
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ples were both fixed in formalin or in alcohol. All
cases have been reviewed and diagnosed according
to years 2000 and 2004 WHO classifications of
Endocrine Tumors.1,2 They included 70 cases of
well-differentiated neuroendocrine tumors (benign
carcinoids) or carcinomas (malignant/atypical carci-
noids) (63 cases from lung, pancreas and gastro-
intestinal tract, and 7 cases of liver or lymph node
metastases in the absence of evident primary
disease), 18 cases of poorly differentiated neuroen-
docrine carcinomas (mainly from lung), 9 cases of
medullary thyroid carcinomas and 7 additional
cases of neuroendocrine tumors from skin, para-
ganglia, thymus and pituitary, as well as 3 cases of
adenocarcinomas with neuroendocrine differentia-
tion of the breast and prostate. In 31 cases, tissue
material was obtained from metastatic deposits, and
in 3 of these cases primary and metastatic lesions
from the same patient could be compared. The study
was approved by the Local Ethic Committee.
Immunohistochemistry
Serial 5-mm thick paraffin sections were collected
onto charged slides and processed by immuno-
histochemistry in a single Institution (Orbassano,
Turin, Italy). In a pilot series of 20 neuroendocrine
tumors, as well as in control sections of normal
pancreatic tissue, alternative polyclonal somatosta-
tin receptor type 2A antibodies (BioTrend, Cologne,
Germany, code SS-800; Santa Cruz Biotechnology,
Santa Cruz, CA, USA, code sc-25676; LifeSpan
Biosciences, Seattle WA, USA, code LS-A998) were
tested. Although all three somatostatin receptor type
2A antibodies were comparable in the majority
of normal and neoplastic specimens in terms of
staining intensity, in our laboratory protocols Bio-
Trend antibody appeared to be more sensitive as
compared to the others, in terms of both presence of
positive internal reference controls (ie blood vessels)
and demonstration of a membranous staining pat-
tern in normal and neoplastic cell populations. It
was therefore selected to be applied to the complete
series of cases and for comparison with in vivo data.
Pre-absorption experiments, performed in control
sections by pre-incubation of the primary antibody
with a 10- to 50-fold excess of blocking peptide
(BioTrend, code SS-801), could confirm the specifi-
city of such antibody. Negative control experiments
by somatostatin receptor type 2A pre-absorption
were therefore performed in each immunohisto-
chemical run. In addition, polyclonal antibodies to
somatostatin receptor types 3 and 5 from three
different sources (BioTrend, codes SS-830 and SS-
838, LifeSpan, codes LS-A2622 and LS-A2639, and
Abcam, Cambridge, UK, codes ab28680 and
ab28618, for subtypes 3 and 5, respectively) were
also tested in the pilot series of 20 cases of
neuroendocrine tumors. According to the prelimin-
ary immunohistochemical findings, Abcam antibo-
dies demonstrated the most intense and reliable
results and were therefore employed on the whole
case series. Moreover, pre-absorption experiments
for BioTrend somatostatin receptor types 3 and 5
antibodies, using the same conditions as for soma-
tostatin receptor type 2A (blocking peptides from
BioTrend, codes SS-831 and SS-839-A, respectively)
failed to confirm the specificity of these latter
primary antibodies, even applying different batches.
For somatostatin receptor immunohistochemistry
the following conditions were applied: antigen
retrieval was performed in pH 6.0 citrate buffer in
a microwave oven (three cycles 5 min each at 750 W)
and the primary antibodies were incubated for 4 h at
371C. Primary antibodies dilutions were 1/3000,
1/1000 and 1/500 for somatostatin receptor types
2A, 3 and 5. Immunoreactions were revealed by a
biotin-free dextran-chain detection system (Envi-
sion, DakoCytomation, Glostrup, Denmark), and
developed using diaminobenzidine as the chromo-
gen. The specificity was also validated in parallel
negative control sections by omitting the primary
antibodies for each immunohistochemical run.
All somatostatin receptor immunohistochemical
findings were analyzed independently by two
observers (MV and IR) in one center (Orbassano,
Turin, Italy).
In 14 selected cases, somatostatin receptor type
2A immunohistochemistry was repeated in a differ-
ent laboratory (Varese) following the same working
conditions, and the results checked to test inter-
laboratory agreement.
Somatostatin Receptor Immunohistochemistry
Scoring System
For somatostatin receptor type 2A a semiquantita-
tive scoring system was designed, taking into
consideration both the subcellular localization and
the extent of the staining, as follows: score 0:
absence of immunoreactivity; score 1: pure cyto-
plasmic immunoreactivity, either focal or diffuse;
score 2: membranous reactivity in less than 50% of
tumor cells, irrespective of the presence of cyto-
plasmic staining; score 3: circumferential membra-
nous reactivity in more than 50% of tumor cells,
irrespective of the presence of cytoplasmic staining.
For somatostatin receptor types 3 and 5, a
cytoplasmic pattern of staining only was observed,
and cases were scored as positive in the presence of
at least 10% of positive tumor cells.
Response to Treatment
Tumor responses was classified according to the
RECIST criteria.24 Complete response was defined as
the absence of radiologically documented lesions.
A partial response was defined as at least a 30%
decrease in the sum of the longitudinal diameter of
target lesions. Progressive disease was defined as at
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least a 20% increase in the sum of the longitudinal
diameter of target lesions or the appearance of one or
more new lesions. Stable disease was defined as
neither a sufficient shrinkage to qualify for partial
response, nor sufficient increase to qualify for
progression disease.
Statistical Analysis
Immunohistochemical results were compared to
somatostatin receptor scintigraphy status and avail-
able clinico-pathological parameters by w2 test using
1 degree of freedom (d.f.¼ 1), and a level of
statistical significance of P¼ 0.05. For statistical
comparison, somatostatin receptor type 2A immu-
nohistochemical scores 0 and 1 were considered
negative, as opposed to scores 2 and 3 (see also
below).
Results
Somatostatin Receptors Distribution in
Neuroendocrine Tumors
Immunohistochemistry
Somatostatin receptor types 2A, 3 and 5 antibodies
showed the specific signal in internal reference
controls (ie blood vessels, pancreatic islets) or in
control sections of both formalin- and alcohol-fixed
tissue samples. In the case of somatostatin receptor
type 2A, pre-absorption experiments abolished the
immunoreactivity (both membranous and cytoplas-
mic patterns) and confirmed the specificity of the
reaction (Figure 1). Grouping somatostatin receptor
type 2A immunohistochemical scores 2 and 3
together as positive (see also below), somatostatin
receptor type 2A was detected in 79% of well-
differentiated neuroendocrine tumors/carcinomas
and in 44% of poorly differentiated neuroendocrine
carcinomas (Table 1). In somatostatin receptor type
2A score 1 cases, the cytoplasmic reactivity was
generally weak to moderate; comparing scores 2 and
3, apart from the percentage of positive tumor cells
which determined the inclusion in one or the other
group, a slightly weaker and often incomplete
membrane staining was observed in score 2 cases,
whereas a strong and circumferential membranous
pattern was characteristic of score 3 cases (Figures 2
and 3). Inter-observer cross validation between the
two independent investigators (MV and IR) was up
to 98%; for discrepant cases agreement was reached
by reviewing the slides at a multihead microscope.
Inter-laboratory cross validation (between the slides
stained in Orbassano and in Varese) showed 100%
scoring agreement in all 14 cases tested.
Somatostatin receptor types 3 and 5 showed a
cytoplasmic pattern only, with very occasional
membrane reinforcement. They were positive in
44 and 71% of well-differentiated neuroendocrine
tumors/carcinomas and in 17 and 28% of poorly
differentiated neuroendocrine carcinomas, respec-
tively for types 3 and 5 (Table 1).
Somatostatin receptor scintigraphy
In vivo somatostatin receptor analysis by 111In-
pentetreotide detected positive binding (including
scores 2–4 according to Kwekkeboom et al23 in 78/
107 cases (73%), with a decreasing percentage of
positive cases comparing well-differentiated lesions
(79%), poorly differentiated neuroendocrine carci-
nomas (44%) and the group miscellaneous neuroen-
docrine tumors (21%).
Correlation of Immunohistochemistry with In Vivo
Data
When checking the correlation of somatostatin
receptor type 2A antibody reactivity with in vivo
data among the different immunohistochemical
groups, scores 2 and 3 showed a high concordance
with somatostatin receptor scintigraphy, being cor-
related to scintigraphic positivity in 87 and 94% of
Figure 1 Intense membranous pattern of staining with somatos-
tatin receptor type 2A antibody (BioTrend, code SS-800) in a
pancreatic islet (a), completely abolished by pre-incubation of the
primary antibody with a 50-fold excess of blocking peptide
(BioTrend, code SS-801) (b).
Table 1 Somatostatin receptors expression in 107 neuroendocrine tumors
Somatostatin receptor
type 2A (scores 2 and 3)
Somatostatin
receptor type 3
Somatostatin
receptor type 5
WD NET/NEC (70 cases) 79% 44% 71%
PD NEC (18 cases) 44% 17% 28%
Others (19 cases) 21% 53% 74%
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cases, respectively, and were grouped together for
further statistical comparison. By contrast, immu-
nohistochemical scores 0 and 1 showed a poor
correlation with somatostatin receptor scintigraphy
results, and therefore were grouped together as
negative for further statistical analysis (Figure 3).
An overall somatostatin receptor type 2A immuno-
histochemistry/somatostatin receptor scintigra-
phy agreement of 77% (82/107 cases, w2 Po0.0001)
was reached (Table 2). Among the 82 concordant
cases, 61 were both methods positive (Figure 4a–c)
and 21 were both methods negative. Consistent
Figure 2 Representative illustration of somatostatin receptor type 2A immunohistochemical scores in surgical (left-sided pictures;
(a) lymph node metastasis of medullary thyroid carcinoma; (c) atypical carcinoid of the lung, (e) well-differentiated neuroendocrine
carcinoma of the pancreas, not functioning) and preoperative cytological (right-sided pictures; (b) liver metastasis of well-differentiated
neuroendocrine carcinoma of the pancreas; (d) lymph node metastasis of well-differentiated neuroendocrine carcinoma, primary
unknown; (f) liver metastasis of well-differentiated neuroendocrine carcinoma of the small ileum) samples. The lesions represented
included: (a, b) Score 1 (a and b) included pure cytoplasmic reactivity, either moderate/strong (a) or weak (b). Score 2 (c and d) was
considered in the presence of a membranous pattern of staining in less than 50% of tumors cells, either in scattered cells with complete
membrane outlining (c) or with partial membrane staining in most tumor cells (d). Score 3 was clearly recognizable by a membranous,
usually intense, staining in more than 50% of tumors cells (e and f).
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concordance rates were observed in the group of
well-differentiated (79%, w2 P¼ 0.05) and poorly
differentiated (94%, w2 Po0.0001) neoplasms. Con-
versely, considering individual tumor locations, a
low concordance rate was observed in the case of
medullary thyroid carcinomas and occult primary
neuroendocrine carcinomas (67 and 54% immuno-
histochemistry/somatostatin receptor scintigraphy
agreement, respectively). The latter group sho-
wed mainly an immunohistochemistry negative/
somatostatin receptor scintigraphy positive profile
(Figure 4d–f).
A rather poor correlation was observed in the
group of preoperative biopsy samples (73% immuno-
histochemistry/somatostatin receptor scintigraphy
agreement, w2 P¼ 0.09) and in patients from whom
metastatic tumor samples were available (65%
immunohistochemistry/somatostatin receptor scin-
tigraphy agreement, w2 P¼ 0.3).
When correlating scintigraphic data with all three
somatostatin receptor antibodies, the overall agree-
ment in the presence of at least one positive
somatostatin receptor type did not change (82/107
cases, 77%), whereas an increase of immunohisto-
chemistry positive/scintigraphy negative cases was
observed (with a loss of ‘specificity’ if considering
111In-pentetreotide scintigraphy the reference
method; Table 3). In 28 patients, all bearing well-
differentiated neuroendocrine carcinomas from pan-
creas and gastrointestinal tract or unknown origin,
homogeneous somatostatin analogue treatment was
administered until progression, consisting in intra-
muscular injection of the long-acting release octreo-
tide (octreotide L-A-R) at a dose of 20 mg every 28
days. Immunohistochemical somatostatin receptor
type 2A status correlated to response to treatment in
75% of cases (21/28); among these 21 concordant
cases, 16 patients had a disease stabilization and
2 cases had a partial response to treatment in
the presence of somatostatin receptor type 2A
immunoreactivity, whereas the 3 remaining cases,
negative to somatostatin receptor type 2A immuno-
Score 0 Score 1
SUBCELLULAR PATTERN
Pure
cytoplasmic
Membranous
usually
incomplete
Membranous
circumferential
(Negative)
(Absent) 1-100%
CONCORDANCE WITH OCTREOSCAN DATA
EXTENSION OF POSITIVE TUMOR CELL POPULATION
<50% >50%
50% 54% 87% 94%
Score 2 Score 3
Figure 3 Schematic illustration of somatostatin receptor type 2A immunohistochemical scoring system and its concordance rate with
111In-pentetreotide in vivo imaging.
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histochemistry, had disease progression. By con-
trast, all seven discordant cases had disease pro-
gression in spite of somatostatin receptor type 2
protein immunohistochemical expression.
Discussion
The wide expression of somatostatin receptors in
neuroendocrine tumors has been largely investi-
gated and led nowadays to the development of
clinically relevant diagnostic and therapeutic stra-
tegies.25 However, which methodology could better
determine the somatostatin receptor status of a given
tumor and could predict its possible visualization
by somatostatin receptor scintigraphy and response
to somatostatin-analogue therapy is far from being
settled in the clinical practice. At present for the
clinicians, somatostatin receptor scintigraphy re-
mains the golden standard method to detect soma-
tostatin receptors. In fact, octreotide scintigraphy
provides information on the whole tumor mass
including metastases and its signal intensity is used
for radiotherapeutic decisions.23 Among alternative
methods, immunohistochemistry seems to be a
reliable tool to detect the somatostatin receptor
profile in neuroendocrine tumors, due to the
following advantages: detection of the receptor
protein (instead of RNA, for example in PCR-based
methods), possibility of detecting the cellular type
expressing the receptor (neoplastic cells vs blood
vessels or reactive lymphocytes, etc), availability of
subtype specific antibodies, applicability in archival
material, low cost/benefit ratio which renders this
method applicable in most laboratories.13,15–17,19,21
On the contrary, major disadvantages are related to
the lack of standardization of the method (from both
technical and interpretation viewpoints) which is a
great limitation in diagnostic applications, the fail-
ure of demonstrating ‘functional’ receptors (as
opposed to autoradiography), and undetermined
sensitivity of the technique, since limited evidence
has been reported on the correlation between
immunohistochemistry and other in vivo techni-
ques. In a recent paper, Korner et al15 tested different
somatostatin receptor type 2A antibodies in differ-
ent human tumors, and correlated the immunohisto-
chemical pattern with previous autoradiographic
data on 37 cases, demonstrating a good correlation
between the two methods applying the same anti-
body selected in our study. Previous reports testing
somatostatin receptor immunohistochemistry in
lung18 and gastrointestinal16 neuroendocrine tumors
and in pheochromocytomas17 in correlation to
somatostatin receptor scintigraphy are limited by
the relative low number of cases compared and by a
general lack of standardization of the immunohisto-
chemical interpretation (ie membranous vs cyto-
plasmic pattern). Therefore, we designed the present
study on a large multicentric series of neuroendo-
crine tumors to validate the reproducibility of the
immunohistochemical method and to compare the
results with somatostatin receptor scintigraphy
imaging.
As a first aim, a practical immunohistochemical
scoring system for the most common somatostatin
receptor subtype—namely type 2A—based on the
percentage of positive tumor cells and the pattern of
Table 2 Concordance between immunohistochemistry and 111In-pentetreotide scintigraphy in detecting the presence of somatostatin
receptor type 2A in neuroendocrine tumors
Total (107) Location Concordant group Discordant group
No. (%) IHC/srs+ IHC/srs No. (%) IHC+/srs IHC/srs+
82 (77) 61 21 25 (23) 6 19
WD Lung (17) 13 (76) 11 2 4 (24) 1 3
NET/NEC Pancreas (28) 24 (86) 23 1 4 (14) 2 2
(70) GI tracta (18) 16 (89) 15 1 2 (11) 2 —
Primary unknown (7) 2 (29) 1 1 5 (71) — 5
PD NEC Lung (13) 12 (92) 5 7 1 (8) 1 —
(18) GI tract (1) 1 — 1 — — —
Primary unknown (4) 4 (100) 2 2 — — —
Others Thyroid MTC (9) 6 (67) 1 5 3 (33) — 3
(19) Merkel cell ca. (3) 2 2 — 1 — 1
Paraganglioma/Pheo (2) 1 1 — 1 — 1
Thymic carcinoid (1) — — — 1 — 1
ADCA with NE diff (3) 1 — 1 2 — 2
Pituitary (1) — — — 1 — 1
Preoperative samples (41) 30 (73) 25 5 11 (27) 3 8
Metastatic samples (31) 20 (65) 17 3 11 (35) 1 10
ADCA, adenocarcinoma; GI, gastrointestinal; IHC, immunohistochemistry; MTC, medullary thyroid carcinoma; NEC, neuroendocrine carcinoma;
NET, neuroendocrine tumor; PD, poorly differentiated; srs, somatostatin receptor scintigraphy; WD, well differentiated.
Bold values represent the total.
Italic values represent the percentage.
a
Including one case of primary WD NEC of the liver and one of the gallbladder.
Somatostatin receptor immunohistochemical scoring
M Volante et al
1178
Modern Pathology (2007) 20, 1172–1182
staining was proposed and assessed. The correlation
with 111In-pentetreotide scintigraphy data indicate
that the higher concordance rates were achieved
only when a membranous pattern of staining was
observed (corresponding to scores 2 and 3), whereas
pure cytoplasmic staining (score 1) presented a
rather poor and random concordance rate and was
therefore considered as negative for further analysis.
Although ‘functional’ mechanisms for somatostatin
receptor type 2A cytoplasmic positivity (ie receptor
Figure 4 Fine-needle aspiration biopsy of a liver metastasis from a well-differentiated pancreatic neuroendocrine carcinoma (a) strongly
expressing somatostatin receptor type 2A by immunohistochemistry (b, immunohistochemical score 3) and clearly visible by 111In-
pentetreotide scintigraphy (c). By contrast, a case of fine-needle aspiration biopsy of a para-caval lymph node metastasis from a well-
differentiated neuroendocrine carcinoma of primary unknown origin (d) showing discrepant results between negative immuno-
histochemistry (e, immunohistochemical score 1) and positive scintigraphy (f).
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internalization) have been discussed in the litera-
ture,26 it might be speculated that in the diagnostic
practice careful search for membranous pattern
(associated or not with a faint cytoplasmic pattern)
should be pursued to define a positive staining. The
same consideration should be deserved for soma-
tostatin receptor types 3 and 5 antibodies, which
showed almost exclusively a cytoplasmic pattern of
staining, and which did not improve significantly
the capability of somatostatin receptor type 2A alone
to correlate with octreotide scintigraphy.
Immunohistochemical somatostatin receptor type
2A scores 2 and 3 were higher, as expected, in
well-differentiated neuroendocrine tumor/carcino-
ma group as compared to poorly differentiated
carcinomas (Table 1), without significant differences
considering the organs of origin, except for the cases
of metastatic samples of unknown primary origin
which showed a lower rate of somatostatin receptor
type 2A expression. When comparing the complete
somatostatin receptor type 2A immunohistochem-
ical data with somatostatin receptor scintigraphy, an
overall high agreement (77%, w2 test Po0.0001) was
observed, irrespective of the degree of differentia-
tion. However, when going through the major causes
of discrepancy, some considerations might be
drawn. First of all, in most instances the source of
discrepancy was related to a negative somatostatin
receptor type 2A immunohistochemical result in the
presence of positive somatostatin receptor scintigra-
phy. In this respect it is difficult, if not useless,
to determine which method is more sensitive or
specific. It is well known, in fact, that false
somatostatin receptor scintigraphy positivity may
be related to necrotic areas or inflammation which
may be frequent within an otherwise somatostatin
receptor negative tumor,18 and therefore immuno-
histochemistry represents, rather than an alterna-
tive, a useful adjunct to somatostatin receptor
scintigraphy. Moreover, the possible role of other
somatostatin receptor subtypes (namely types 3 and
5), which possess high affinity for the currently
available somatostatin analogues, was investigated,
although their analysis did not improve the overall
concordance between scintigraphy and immunohis-
tochemistry, and their application in the clinical
practice still needs the availability of satisfactory
commercial reagents, in our opinion.
By contrast, it should be speculated that immu-
nohistochemistry may present a lower sensitivity
than 111In-pentetreotide scintigraphy and the tissue
material investigated may not represent the soma-
tostatin receptor type 2A expression pattern of the
whole tumor. The frequent heterogeneity of soma-
tostatin receptor distribution in tumor tissues may
cause discrepant (either positive or negative) im-
munohistochemical results as compared to soma-
tostatin receptor scintigraphy, and this is more
evident in our study when analyzing separately
preoperative (ie small tissue fragments) and meta-
static samples, which showed lower concordance
rates (73 and 65%, w2 P¼ 0.09 and P¼ 0.3, respec-
tively). Technical artifacts related to tissue fixation
and preservation are instead unlikely to explain
discrepancies between the two methods considered,
since comparable results were observed in both
formalin and alcohol-fixed tissue specimens, and
irrespective of the length of tissue storage.
It is important to note that the correlation with
somatostatin receptor scintigraphy represents only
one side of the matter, and the predictive value of
somatostatin receptor immunohistochemistry in
determining the clinical response to somatostatin
analogues treatment would have comparable if not
greater clinical impact. Such a correlation was
limited in our study because of heterogeneous
medical treatments of the patients and different
intrinsic biological behavior of the diseases (ie from
well- to poorly differentiated forms). However, in a
group of 28 cases with comparable disease and
therapeutic schedules, positive somatostatin recep-
tor type 2A immunohistochemistry correlated with
somatostatin analogues response in up to 75% of
cases. Large clinical trials should be designed to
validate the role of somatostatin receptor immuno-
histochemical profile in the prediction of clinical
response.
In conclusion, our data indicate that (i) immuno-
histochemistry represents a reliable and useful
method to characterize somatostatin receptor ex-
pression in neuroendocrine tumors, with special
reference to type 2A, provided that accurate
methodological conditions and standardized inter-
pretation of the immunohistochemical results
(membranous vs cytoplasmic pattern) are obtained;
(ii) a standardized scoring system for immunohis-
Table 3 Concordance between immunohistochemistry and 111In-pentetreotide scintigraphy, according to somatostatin receptor type
considered
Somatostatin receptor
type 2A
Somatostatin receptor
type 2A and/or 3
Somatostatin receptor
type 2A and/or 5
At least one somatostatin
receptor type
Overall agreement 77% 80% 77% 77%
Sensitivitya 80% 91% 89% 93%
Specificitya 67% 60% 41% 35%
a
Sensitivity and specificity were calculated considering arbitrarily 111In-pentetreotide scintigraphy the reference method.
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tochemistry is proposed, with good clinical corre-
lates; which support its role as a useful adjunct to
somatostatin receptor scintigraphy in the clinical
management of these patients, providing additional
information on the tissue distribution of the recep-
tors, heterogeneity among primary and metastatic
lesions, and picking up false-positive scintigraphic
images; (iii) somatostatin receptor type 2A immuno-
histochemistry may predict clinical response to
somatostatin analogue therapy, although further
validation on large series is needed.
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